Frontiers in Oncology is delighted to present “Quick Reads in Pulmonary Neuroendocrine Tumors”, a collection of high-quality Mini-Reviews aimed to provide a valuable resource for academics and clinicians to stay up-to-date to with the key advances in the pathogenesis, diagnosis, and treatment of pulmonary neuroendocrine tumors.
Neuroendocrine tumors (NETs) are a rare and heterogeneous type of cancer that develops from cells of the neuroendocrine system. NETs can occur in many parts of the body, but they most commonly arise from the gastrointestinal tract, pancreas, and lungs.
NETs can be classified as functional or non-functional tumors, according to their ability to produce and secrete hormones and biogenic amines. Functional NETs usually cause recognizable clinical hormone syndromes, while non-functional tumors can be difficult to detect, due to the lack of symptoms. Pulmonary NETs are classified into typical and atypical carcinoids and display a wide range of clinical behavior, with significant differences in growth rate and aggressiveness.
Treatment of Pulmonary NETs depends on several factors, including the type, location, and stage of the tumor. Surgery is often the first line of treatment for localized pulmonary NETs. For advanced or metastatic NETs, other treatments like somatostatin analogs, mTOR inhibitor Everolimus, chemotherapy, or peptide receptor radionuclide therapy (PRRT) may be considered. Diagnosis and treatment of pulmonary NETs are complex, due to their relative rarity and heterogeneous behavior. This Research Topic aims to provide a platform to discuss the most relevant advances in the field. We welcome Mini-Review Articles focused on, but not limited to:
- advances in diagnosis and molecular classification of pulmonary neuroendocrine tumors;
- epidemiological evolution and clinical characteristics of pulmonary neuroendocrine tumors;
- clinically relevant biomarkers, including predictive factors of response and survival;
- therapeutic strategies;
- characterization of (hereditary) syndromes associated with pulmonary neuroendocrine tumors, including diffuse neuroendocrine cell hyperplasia (DIPNECH).
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords:
Neuroendocrine tumors, biomarker, cancer therapy, tumor classification, pulmonary
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Frontiers in Oncology is delighted to present “Quick Reads in Pulmonary Neuroendocrine Tumors”, a collection of high-quality Mini-Reviews aimed to provide a valuable resource for academics and clinicians to stay up-to-date to with the key advances in the pathogenesis, diagnosis, and treatment of pulmonary neuroendocrine tumors.
Neuroendocrine tumors (NETs) are a rare and heterogeneous type of cancer that develops from cells of the neuroendocrine system. NETs can occur in many parts of the body, but they most commonly arise from the gastrointestinal tract, pancreas, and lungs.
NETs can be classified as functional or non-functional tumors, according to their ability to produce and secrete hormones and biogenic amines. Functional NETs usually cause recognizable clinical hormone syndromes, while non-functional tumors can be difficult to detect, due to the lack of symptoms. Pulmonary NETs are classified into typical and atypical carcinoids and display a wide range of clinical behavior, with significant differences in growth rate and aggressiveness.
Treatment of Pulmonary NETs depends on several factors, including the type, location, and stage of the tumor. Surgery is often the first line of treatment for localized pulmonary NETs. For advanced or metastatic NETs, other treatments like somatostatin analogs, mTOR inhibitor Everolimus, chemotherapy, or peptide receptor radionuclide therapy (PRRT) may be considered. Diagnosis and treatment of pulmonary NETs are complex, due to their relative rarity and heterogeneous behavior. This Research Topic aims to provide a platform to discuss the most relevant advances in the field. We welcome Mini-Review Articles focused on, but not limited to:
- advances in diagnosis and molecular classification of pulmonary neuroendocrine tumors;
- epidemiological evolution and clinical characteristics of pulmonary neuroendocrine tumors;
- clinically relevant biomarkers, including predictive factors of response and survival;
- therapeutic strategies;
- characterization of (hereditary) syndromes associated with pulmonary neuroendocrine tumors, including diffuse neuroendocrine cell hyperplasia (DIPNECH).
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords:
Neuroendocrine tumors, biomarker, cancer therapy, tumor classification, pulmonary
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.